NCT01639456 arm group 1440a373d8bb996ce214a52fdae341e7 [clinicaltrials_resource:NCT01639456/arm-group/1440a373d8bb996ce214a52fdae341e7]
CliniMACS® CD3 and CD19 Reagent System [clinicaltrials_resource:1225ac738fd69e3c6eb8224ca4371fba]Fludarabine [clinicaltrials_resource:2d4b0d594d84f938846d0c9632c6d8cc]Cyclophosphamide [clinicaltrials_resource:3349e68263b1eb298b4bb48c19ba26a7]Aldesleukin [clinicaltrials_resource:43dd63701c32196217c97ee82e3ffeba]CD3-/CD19- natural killer cells [clinicaltrials_resource:ffcfa794b1e9cc92b2b0811ce6361871]clinicaltrials:NCT01639456
arm group [clinicaltrials_vocabulary:arm-group]
NCT01639456 arm group 1440a373d8bb996ce214a52fdae341e7 [clinicaltrials_resource:NCT01639456/arm-group/1440a373d8bb996ce214a52fdae341e7]
Bio2RDF identifier
NCT01639456/arm-group/1440a373d8bb996ce214a52fdae341e7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 40a373d8bb996ce214a52fdae341e7
description [clinicaltrials_vocabulary:description]
Patients receive the apheresis ...... , Fludarabine and Aldesleukin.
identifier
clinicaltrials_resource:NCT01639456/arm-group/1440a373d8bb996ce214a52fdae341e7
title
NCT01639456 arm group 1440a373d8bb996ce214a52fdae341e7
@en
type
label
NCT01639456 arm group 1440a373 ...... 0a373d8bb996ce214a52fdae341e7]
@en